Table 3 The experimental results of the DAEGCNDF model based on 10-fold cross-validation
Dataset: | MDAID | |||||
|---|---|---|---|---|---|---|
Testing set | Acc(%) | Pre (%) | Recall (%) | F1-score (%) | AUC (%) | AUPR (%) |
1 | 92.34 | 92.35 | 92.33 | 92.34 | 97.71 | 98.01 |
2 | 90.68 | 90.62 | 90.68 | 90.65 | 97.42 | 97.12 |
3 | 90.01 | 90.03 | 90.01 | 90.01 | 96.65 | 96.37 |
4 | 89.90 | 89.89 | 89.86 | 89.87 | 96.04 | 95.65 |
5 | 91.01 | 90.97 | 91.05 | 91.00 | 97.42 | 97.61 |
6 | 91.79 | 91.79 | 91.79 | 91.79 | 97.55 | 97.71 |
7 | 90.12 | 90.11 | 90.19 | 90.12 | 95.87 | 95.36 |
8 | 89.67 | 89.65 | 89.69 | 89.66 | 96.36 | 96.40 |
9 | 90.22 | 90.34 | 90.13 | 90.19 | 97.03 | 96.87 |
10 | 93.11 | 93.14 | 93.10 | 93.11 | 97.90 | 97.90 |
Average | 90.89 ± 1.16 | 90.89 ± 1.17 | 90.88 ± 1.16 | 90.87 ± 1.17 | 97.00 ± 0.72 | 96.90 ± 0.94 |
Dataset: | HMDAD | |||||
|---|---|---|---|---|---|---|
Testing set | Acc(%) | Pre (%) | Recall (%) | F1-score (%) | AUC (%) | AUPR (%) |
1 | 91.11 | 91.25 | 90.84 | 91.00 | 97.66 | 97.65 |
2 | 90.00 | 90.00 | 90.18 | 89.89 | 97.07 | 9755 |
3 | 85.56 | 86.25 | 85.87 | 85.54 | 94.85 | 94.86 |
4 | 86.67 | 86.84 | 86.84 | 86.67 | 96.14 | 96.28 |
5 | 86.67 | 87.16 | 86.94 | 86.67 | 95.45 | 96.30 |
6 | 83.33 | 83.90 | 83.78 | 83.33 | 93.25 | 94.78 |
7 | 92.22 | 92.16 | 92.26 | 92.20 | 97.17 | 97.49 |
8 | 90.00 | 90.18 | 90.00 | 90.00 | 97.93 | 98.11 |
9 | 88.89 | 89.00 | 88.69 | 88.80 | 96.78 | 96.82 |
10 | 86.67 | 86.74 | 86.67 | 86.66 | 96.94 | 97.37 |
Average | 88.11 ± 2.77 | 88.35 ± 2.58 | 88.21 ± 2.62 | 88.08 ± 2.75 | 96.32 ± 1.44 | 96.72 ± 1.16 |